Traders Are Bullish AVROBIO, Inc. (AVRO) After The Stock Formed Double Top Pattern

August 10, 2018 - By Margaret Guttierez

The chart of AVROBIO, Inc. (AVRO) shows a double top with $40.29 target or 6.00 % above today’s $38.01 share price. The 9 months chart pattern indicates low risk for the $909.84M company. It was reported on Aug, 10 by If the $40.29 price target is reached, the company will be worth $54.59M more. Double tops are rare but powerful chart patterns.

The stock decreased 0.13% or $0.05 during the last trading session, reaching $38.01. About 2,222 shares traded. AVROBIO, Inc. (NASDAQ:AVRO) has 0.00% since August 10, 2017 and is . It has underperformed by 12.57% the S&P500.

More notable recent AVROBIO, Inc. (NASDAQ:AVRO) news were published by: which released: “Newly Public Gene Therapy Biotech Avrobio Picks Up 2 Sell-Side Bulls” on July 16, 2018, also with their article: “60 Biggest Movers From Yesterday” published on July 27, 2018, published: “51 Biggest Movers From Yesterday” on July 19, 2018. More interesting news about AVROBIO, Inc. (NASDAQ:AVRO) were released by: and their article: “AVROBIO, Inc. Reports Second Quarter 2018 Financial Results and Provides Business Update” published on August 09, 2018 as well as‘s news article titled: “The Week Ahead: Apple And Tesla Earnings, FOMC Meeting, Sonos IPO” with publication date: July 31, 2018.

AVROBIO, Inc., a clinical stage gene therapy company, focuses on developing ex vivo lentiviral gene therapies to treat rare diseases following a single dose. The company has market cap of $909.84 million. The company's gene therapies employ hematopoietic stem cells that are extracted from the patient and modified with lentiviral vectors to insert a functional copy of the gene that is defective in the target disease. It currently has negative earnings. The Company’s lead product candidate is AVR-RD-01, which is in ongoing Phase II clinical trial and investigator-sponsored Phase I clinical trial for the treatment of fabry disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.